levonorgestrel + ethinyl estradiol
Commercial- Indications
- Contraception
Company intelligence / Profile preview
Twirla®, the company’s lead product—a once-weekly combined hormonal contraceptive patch—has completed Phase 3 trials demonstrating safety and efficacy. It was approved by the FDA in February 2020. Post-marketing surveillance has shown a favorable safety profile consistent with clinical trial data. All other pipeline programs are currently on hold as the company focuses on commercializing Twirla.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Agile Therapeutics.